Skip to main content

Basel Healthtech fund successfully closed

| News

Basel Healthtech fund successfully closed


The venture capital firm MTIP has announced the successful closing of its FUND II. It is one of the first funds to invest in innovative European Healthtech firms in the growth phase.

Christoph Kausch, Managing Partner and Co-Founder of MTIP (img: MTIP)

MTIP has completed the fundraising phase for its second fund. As the Basel-based private equity firm announced on December 7, it raised a total of 250 million US dollars in capital commitments under its MTIP Fund II instead of the original target of 225 million US dollars.

The “dark green”, sustainability-focused fund is one of the first of its kind to specialize in the Healthtech sector. It invests in digital health companies and digitally-connected medical technology firms with the aim of supporting international expansion plans. “We are excited to announce the successful closing of our second fund and continue our mission to build the Healthtech leaders of tomorrow”, explains Christoph Kausch, Managing Partner at MTIP, in the press release.

New and existing investors in the fund included institutional investors, pension funds, family offices, hospitals, foundations and the health insurance firm Sanitas, further details of which can be found in the press release. Andreas Schönenberger, CEO of Sanitas, praised MTIP’s “unique expertise in Healthtech” that allows it to foster innovation “in this under-served private equity sector”.

MTIP writes further in the press release that it has already made successful investments in five companies as part of its MTIP Fund II: OvivaTrialbeeKoa HealthIntelligencia and Mediktor.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.